Absolute changes between baseline and week 12 in parameters by treatment group
| Baseline (week 0) | Week 12 | Adjusted changes (week 12–week 0) | |||||
|---|---|---|---|---|---|---|---|
| Parameter | Placebo* (n=43) | Etanercept* (n=39) | Placebo* (n=43) | Etanercept* (n=39) | Placebo† (n=43) | Etanercept† (n=39) | p Value |
| BASDAI (0–100) | 58±15 | 64±12 | 45±19 | 37±26 | −14±20 | −26±20 | 0.008 |
| BASFI (0–100) | 57±19 | 63±20 | 48±21 | 41±29 | −10±18 | −22±18 | 0.004 |
| BASMI, (0–10) | 5.8±1.3 | 5.7±1.4 | 5.6±1.3 | 5.1±1.7 | −0.20±0.65 | −0.57±0.65 | 0.011 |
| Total back pain, (0–100) | 61±20 | 70±16 | 48±22 | 38±28 | −15±24 | −29±24 | 0.010 |
| CRP, mg/l | 17±19 | 25±31 | 18±20 | 6±8 | −1±14 | −16±14 | <0.0001 |
| ASDAS-CRP | 3.63±0.76 | 3.90±0.71 | 3.18±0.95 | 2.3±0.97 | −0.49±0.87 | −1.51±0.87 | <0.0001 |
↵* Data are mean±SD.
↵† Data are adjusted mean±SD from a mixed model ANCOVA with an autoregressive correlation structure with treatment groups, visits and their interaction as fixed factors and baseline scores as a covariate.
ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score-CRP; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C reactive protein.